Guohui Zhang1, Rebecca A Gibson2, Marie McDonald2, Pengfei Liang3, Po Wei Kang1, Jingyi Shi1, Huanghe Yang3,4, Jianmin Cui1, Mohamad A Mikati2,4. 1. Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA. 2. Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA. 3. Department of Biochemistry, Duke University Medical Center, Durham, North Carolina, USA. 4. Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, USA.
Abstract
BACKGROUND: The mutations of KCNMA1 BK-type K+ channel have been identified in patients with various movement disorders. The underlying pathophysiology and corresponding therapeutics are lacking. OBJECTIVES: To report our clinical and biophysical characterizations of a novel de novo KCNMA1 variant, as well as an effective therapy for the patient's dystonia-atonia spells. METHODS: Combination of phenotypic characterization, therapy, and biophysical characterization of the patient and her mutation. RESULTS: The patient had >100 dystonia-atonia spells per day with mild cerebellar atrophy. She also had autism spectrum disorder, intellectual disability, and attention deficit hyperactivity disorder. Whole-exome sequencing identified a heterozygous de novo BK N536H mutation. Our biophysical characterization demonstrates that N536H is a gain-of-function mutation with markedly enhanced voltage-dependent activation. Remarkably, administration of dextroamphetamine completely suppressed the dystonia-atonia spells. CONCLUSIONS: BK N536H is a gain-of-function that causes dystonia and other neurological symptoms. Our stimulant therapy opens a new avenue to mitigate KCNMA1-linked movement disorders.
BACKGROUND: The mutations of KCNMA1 BK-type K+ channel have been identified in patients with various movement disorders. The underlying pathophysiology and corresponding therapeutics are lacking. OBJECTIVES: To report our clinical and biophysical characterizations of a novel de novo KCNMA1 variant, as well as an effective therapy for the patient's dystonia-atonia spells. METHODS: Combination of phenotypic characterization, therapy, and biophysical characterization of the patient and her mutation. RESULTS: The patient had >100 dystonia-atonia spells per day with mild cerebellar atrophy. She also had autism spectrum disorder, intellectual disability, and attention deficit hyperactivity disorder. Whole-exome sequencing identified a heterozygous de novo BK N536H mutation. Our biophysical characterization demonstrates that N536H is a gain-of-function mutation with markedly enhanced voltage-dependent activation. Remarkably, administration of dextroamphetamine completely suppressed the dystonia-atonia spells. CONCLUSIONS: BK N536H is a gain-of-function that causes dystonia and other neurological symptoms. Our stimulant therapy opens a new avenue to mitigate KCNMA1-linked movement disorders.
Authors: Wei Du; Jocelyn F Bautista; Huanghe Yang; Ana Diez-Sampedro; Sun-Ah You; Lejin Wang; Prakash Kotagal; Hans O Lüders; Jingyi Shi; Jianmin Cui; George B Richerson; Qing K Wang Journal: Nat Genet Date: 2005-06-05 Impact factor: 38.330
Authors: Su Mi Park; Cooper E Roache; Philip H Iffland; Hans J Moldenhauer; Katia K Matychak; Amber E Plante; Abby G Lieberman; Peter B Crino; Andrea Meredith Journal: Elife Date: 2022-07-12 Impact factor: 8.713
Authors: Patrick Kratschmer; Simon A Lowe; Edgar Buhl; Ko-Fan Chen; Dimitri M Kullmann; Alan Pittman; James J L Hodge; James E C Jepson Journal: Mov Disord Date: 2021-01-15 Impact factor: 9.698
Authors: Ping Dong; Yang Zhang; Arsen S Hunanyan; Mohamad A Mikati; Jianmin Cui; Huanghe Yang Journal: Proc Natl Acad Sci U S A Date: 2022-03-14 Impact factor: 12.779